Scalper1 News
Biotech Insmed (INSM) said a phase-two trial of its lung-infection drug Arikayce failed to meet its primary endpoint but met its secondary endpoint, sending the stock down 12% in heavy midday trading on the stock market today. The pre-specified endpoint of the trial was a certain reduction in the density of mycobacteria on day 84 of the trial. Insmed said that patients in the Arikayce group didn’t meet that endpoint significantly more often than Scalper1 News
Scalper1 News